Atonic Bladder

Definition

Pathophysiology

• Destruction of sensory (afferent) nerve fibers: The stretch signals from the bladder never reach the cord, so the micturition reflex cannot be triggered. The bladder simply fills to capacity and overflows. (Guyton & Hall, p.334)
• Damage to motor (efferent) fibers or sacral cord: The detrusor cannot contract even if stretch is sensed.
• Repeated overdistension: Mechanical over-stretching of the detrusor leads to fibrosis and permanent atonia or hypotonia. (Adams & Victor's Principles of Neurology)

Causes

Neurological Causes

Structural/Obstructive Causes

• Prostatic hypertrophy - chronic outlet obstruction leads to repeated overdistension and eventual detrusor decompensation
• Severe cystocele in women
• Postoperative urinary retention (especially after pelvic/perineal surgery or spinal anesthesia)

Pharmacological Causes

• Anticholinergic drugs (tricyclic antidepressants, antihistamines e.g. diphenhydramine, antipsychotics)
• Sympathomimetics (pseudoephedrine)
• Opioids

Other

• Spinal shock (acute phase after suprasacral spinal cord injury) - the bladder is areflexic and acontractile, lasting 6-12 weeks (sometimes up to 1 year) before reflexes recover (Bradley & Daroff's Neurology)
• DIDMOAD syndrome (Wolfram syndrome) - urinary tract abnormalities including atonic bladder
• Neurosyphilis - Argyll Robertson pupils, absent reflexes, atonic bladder (Andrews' Diseases of the Skin)

Clinical Features

• Urinary retention - inability to void despite a full bladder
• Overflow incontinence - constant dribbling of small amounts of urine as pressure overcomes sphincter resistance
• Large post-void residual (PVR) volume
• Absent or reduced urge to void (impaired bladder sensation)
• Bladder distension - palpable/percussible suprapubic mass
• Absent bulbocavernosus and cremasteric reflexes if peripheral sacral fibers are involved
• Predisposition to recurrent UTIs, ureteral reflux, hydronephrosis, and renal calculi

Comparison: Atonic Bladder vs. Detrusor-External Sphincter Dyssynergia (DESD)

Treatment and Management

1. Acute Phase (Spinal Shock)

• Insert a Foley catheter or begin clean intermittent catheterization (CIC) immediately to prevent overdistension
• CIC every 4 hours, keeping bladder volumes < 500 mL
• Monitor for recovery of bladder reflexes over 6-12 weeks

2. Bladder Emptying - Primary Methods

• Avoids the high complication rates of indwelling catheters (infection, bladder cancer, renal stones, strictures, diverticula)
• Performed every 4-6 hours
• Self-catheterization is ideal when the patient has adequate hand function and motivation

• Credé maneuver: Manual direct pressure over the suprapubic area to express urine
• Valsalva maneuver: Increases intraabdominal pressure to assist voiding
• These are used when CIC is not feasible

• For patients who lack motivation, have limited hand function, or cannot receive adequate caregiver support
• Long-term use is discouraged due to complications

3. Pharmacological Treatment

4. Treat the Underlying Cause

• Diabetes: Optimize glycemic control to slow autonomic neuropathy progression
• Syphilis (tabes dorsalis): Penicillin treatment
• BPH: Alpha-blockers, 5-alpha reductase inhibitors, or transurethral resection of prostate (TURP)
• Drug-induced: Discontinue offending agent where possible

5. Prevention of Complications

• Urinary tract infections: Maintain hygiene with CIC; treat infections promptly; prophylactic antibiotics are controversial
• Upper tract protection: Monitor for hydronephrosis and vesicoureteral reflux with imaging; determine detrusor leak-point pressure (DLPP - threshold: 40 cmH2O)
• Renal function monitoring: Regular creatinine, renal ultrasound

6. Surgical Options (When Conservative Treatment Fails)

Summary Table

• Guyton & Hall Textbook of Medical Physiology - Abnormalities of Micturition
• Bradley & Daroff's Neurology in Clinical Practice - Spinal Cord Injury and Bladder Function
• Adams & Victor's Principles of Neurology - Therapy of Disordered Micturition
• Goodman & Gilman's Pharmacological Basis of Therapeutics - Bethanechol
• Neuroanatomy through Clinical Cases 3rd Ed. - Bowel, Bladder, and Sexual Function
• Recent review: Neurogenic Lower Urinary Tract Dysfunction (Wiener & Chaudhry, Urol Clin North Am, 2023 - PMID 37385704) and The Ideal Neurogenic Bladder Management Team (Hogue & Kennelly, Urol Clin North Am, 2024 - PMID 38609201)

Recent Advances in Atonic (Neurogenic) Bladder - 2023 to 2026

1. Pharmacological Advances

Beta-3 Adrenergic Agonists (Emerging First-Line Consideration)

• A 2024 meta-analysis (Welk et al., Western University) showed mirabegron increased bladder capacity by an average of 41 mL and reduced detrusor pressure by 20 cmH2O, with a favorable cardiovascular safety profile.
• A 2025 opinion paper published in Neurourology and Urodynamics by Fishberg et al. (University of Toronto) argues beta-3 agonists should be considered first-line over antimuscarinics in neurogenic LUTD, due to their absence of cognitive/anticholinergic side effects. This remains emerging thinking, not yet reflected in major guidelines.
• Vibegron (newer beta-3 agonist) is under investigation with even fewer drug interactions than mirabegron.

Botulinum Toxin A (Botox) - Evolving Role

• A 2024 systematic review in Spinal Cord confirmed sustained efficacy of intravesical onabotulinumtoxinA for SCI-related NDO, extending follow-up duration from prior trials.
• A 2025-2026 early-phase trial (interim data) reported an 88% reduction in incontinence episodes by week 12, sustained through week 24. These are preliminary findings from a small cohort but are generating strong interest.
• Duration of effect ranges from 6-9 months per injection, prompting research into sustained-release formulations and optimal redosing intervals.

Distigmine Bromide (Cholinesterase Inhibitor)

• Used in some centers as an alternative to bethanechol for atonic bladder, with recent small case series showing modest improvement in detrusor contractility in patients with MS, spina bifida, and spinal cord injury. Evidence remains limited.

2. Neuromodulation Advances

Sacral Neuromodulation (SNM) - Expanded Use

• Recent studies show SNM can improve both bladder storage and emptying in select patients with Parkinson's disease, MS, SCI, and spina bifida - reducing catheterization frequency and medication use.
• Closed-loop (adaptive) SNM systems have emerged as a major technological leap: these devices sense real-time bladder filling signals and automatically adjust stimulation parameters, rather than delivering fixed continuous stimulation. This personalized, responsive approach shows promise for better outcomes and battery life.
• MRI-compatible SNM devices now allow full-body MRI scanning - previously a major limitation since many neurogenic bladder patients need MRI for their underlying conditions (MS, spinal cord pathology).
• Review: Off-Label but On-Target: Sacral Neuromodulation for Neurogenic Bladder Dysfunction (Vogel & Nakib, Curr Urol Rep, 2025 - PMID 40549020)

Posterior Tibial Nerve Stimulation (PTNS) - Non-Invasive

• A 2024 review (Alsannan et al., Frontiers in Urology - PMID 40777094) assessed 10 years of evidence on PTNS alongside SNM and pudendal neuromodulation (PNM).
• Newer transcutaneous (non-needle) PTNS devices are being validated, making outpatient treatment easier.
• PTNS is emerging as useful for patients who are poor surgical candidates or refuse implantation.

Vagus Nerve Stimulation (VNS) - Emerging Frontier

Pudendal Nerve Stimulation

• Targets the afferent limb of the bladder reflex arc at the pudendal nerve. Emerging evidence shows it may be superior to sacral stimulation in some patients with atonic/underactive bladder, as it more directly recruits the urethral sensory pathway.

3. Regenerative Medicine and Tissue Engineering

Stem Cell Therapy

• A systematic review and meta-analysis (Salehi-Pourmehr et al., Int Urogynecol J, 2022 - PMID 34767058) confirmed that stem cell therapy (mainly mesenchymal stem cells and muscle-derived stem cells) shows functional improvements in neurogenic bladder in animal and early human studies.
• A 2023 review (Ou et al., Stem Cell Rev Rep - PMID 37115409) focused specifically on SCI-induced NLUTD, showing that stem cells delivered directly to the spinal cord or bladder wall improve detrusor contractility by promoting neural regeneration and reducing fibrosis.
• Mechanisms under study: Paracrine signaling (growth factors, exosomes), direct neuronal differentiation, and immunomodulation to reduce neuroinflammation.
• Current status: Still largely experimental. No stem cell therapy has received regulatory approval specifically for atonic bladder, but several Phase I/II trials are ongoing.

Tissue Engineering - Bladder Scaffolds

• A 2023 review (Topoliova et al., Medicina - PMID 37629705) examined bioengineered bladder constructs combining biodegradable scaffolds with autologous cells.
• Progress in 3D bioprinting of bladder tissue with smooth muscle and urothelial cells is an active area, aiming to provide replacement bladder tissue for patients requiring cystectomy.

Anti-fibrotic Approaches

• 2025 research (Wang et al., Biochem Pharmacol - PMID 40683470) identified the STING pathway as a driver of bladder epithelial pyroptosis and fibrosis in neurogenic bladder. Targeting STING reduced fibrosis in animal models - a potential new pharmacological target.
• NF-kB pathway inhibition has also been shown to reduce pyroptosis and bladder wall fibrosis (Chen et al., 2023 - PMID 37446339), protecting long-term bladder compliance.

4. Artificial Intelligence (AI) in Diagnosis and Management

• Machine learning (ML) models are being trained on urodynamic data to classify bladder dysfunction type (atonic vs. spastic vs. mixed) automatically and predict progression.
• Deep learning algorithms applied to cystoscopy images, ultrasound, and MRI are improving structural diagnosis of neurogenic bladder complications (trabeculation, diverticula, VUR).
• AI-driven urodynamic interpretation: Reducing inter-observer variability in reading cystometry traces.
• Wearable sensors + AI: Smart catheters and bladder sensors are being developed to provide continuous monitoring of bladder pressure and filling, feeding data into AI systems that alert patients when to catheterize - potentially replacing fixed-schedule CIC with on-demand, personalized catheterization schedules.

5. Urinary Microbiome Research

• Next-generation sequencing has characterized distinct microbiome profiles in neurogenic bladder patients.
• Dysbiosis is associated with recurrent UTIs and resistance to conventional antibiotics.
• Microbiome-targeted therapies (probiotics, bacteriophage therapy, microbiome restoration) are being explored as alternatives to chronic antibiotics, addressing the major problem of antibiotic resistance in this population.

6. Interdisciplinary Engineering Advances

• Closed-loop implantable systems that sense and respond to bladder state in real-time
• Smart catheters with embedded sensors for pressure, infection biomarkers, and flow
• Minimally invasive neural interfaces for more precise neuromodulation
• Patient-centered technology design - a key theme, ensuring devices are practical for daily life

Summary of Key Advances

• Sacral Neuromodulation for Neurogenic Bladder - Vogel & Nakib, Curr Urol Rep 2025 (PMID 40549020)
• Vagus Nerve Stimulation for SCI Urinary Dysfunction - Sargusingh et al., Bioelectron Med 2025 (PMID 40542413)
• Engineering Advances in NLUTD - NBRG Report 2026 - Salazar et al., Neurourol Urodyn June 2026 (PMID 42370776)
• Urinary Microbiome in Neurogenic Bladder - Zhang et al., Front Cell Infect Microbiol 2025 (PMID 40235931)
• AI in Bladder Pathophysiology Diagnosis - Mahapatra, Bladder 2025 (PMID 40747464)

Authors Behind Recent Advances in Atonic/Neurogenic Bladder

1. Beta-3 Agonists (Mirabegron/Vibegron)

• Led the 2024 meta-analysis showing mirabegron increased bladder capacity by 41 mL and reduced detrusor pressure by 20 cmH2O.

• Published a 2025 opinion piece in Neurourology and Urodynamics arguing beta-3 agonists should be considered first-line in neurogenic LUTD.

2. Botulinum Toxin A

3. Sacral Neuromodulation (SNM)

• 2025 review: "Off-Label but On-Target: Sacral Neuromodulation for Neurogenic Bladder Dysfunction"
• Published in Current Urology Reports (PMID 40549020)

• 2024 review: "Updates in Pelvic Neuromodulation: the Role of Pelvic Neuromodulation in Pelvic Disorders"
• Published in Frontiers in Urology (PMID 40777094)

• 2025 review on sacral neuromodulation in women's pelvic floor dysfunction
• Published in Archives of Gynecology and Obstetrics (PMID 40956334)

4. Vagus Nerve Stimulation (VNS) - Neuroplasticity Approach

• 2025 perspective: "Enhancing Neuroplasticity via Vagus Nerve Stimulation to Improve Urinary Dysfunction after Spinal Cord Injury"
• Published in Bioelectronic Medicine (PMID 40542413)

5. Stem Cell Therapy

• Systematic review and meta-analysis: "Clinical Application of Stem Cell Therapy in Neurogenic Bladder"
• Published in International Urogynecology Journal (PMID 34767058)

• 2023 review: "Stem Cell Therapy in Spinal Cord Injury-Induced Neurogenic Lower Urinary Tract Dysfunction"
• Published in Stem Cell Reviews and Reports (PMID 37115409)

• 2023 review: "Tissue Engineering and Stem Cell Therapy in Neurogenic Bladder Dysfunction: Current and Future Perspectives"
• Published in Medicina (PMID 37629705)

6. Anti-Fibrotic / Molecular Pathway Research

• 2025 study: "Targeting STING Alleviates Pyroptosis of Bladder Epithelial Cells and Ameliorates Bladder Fibrosis in Neurogenic Bladder"
• Published in Biochemical Pharmacology (PMID 40683470)

• 2023 study: "Inhibition of the NF-kB Signaling Pathway Alleviates Pyroptosis in Bladder Epithelial Cells and Neurogenic Bladder Fibrosis"
• Published in International Journal of Molecular Sciences (PMID 37446339)

7. Artificial Intelligence in Bladder Diagnosis

• 2025 review: "Artificial Intelligence for Diagnosing Bladder Pathophysiology: An Updated Review and Future Prospects"
• Published in Bladder (San Francisco) (PMID 40747464)

8. Urinary Microbiome Research

• 2025 review: "Exploring Urinary Microbiome: Insights into Neurogenic Bladder and Improving Management of Urinary Tract Infections"
• Published in Frontiers in Cellular and Infection Microbiology (PMID 40235931)

9. Engineering Advances / Interdisciplinary Research (NBRG Report)

• June 2026 report: "Engineering Advances in Neurogenic Lower Urinary Tract Dysfunction (NLUTD): Current State and Future Directions"
• A report from the Neurogenic Bladder Research Group (NBRG)
• Published in Neurourology and Urodynamics (PMID 42370776)

Quick Reference Summary Table

Denervated Bladder vs. Atonic Bladder - Key Differences

Definitions

Atonic Bladder

• Neurological causes (neurogenic)
• Mechanical/myogenic causes (muscle damage, fibrosis)
• Pharmacological causes (drug-induced)
• Chronic overdistension

• Detrusor underactivity - reduced strength/duration of contraction
• Acontractile detrusor - no demonstrable detrusor contraction on urodynamics
• Neurogenic acontractile detrusor - when a neurological cause is confirmed

Denervated Bladder

1. A specific identifiable nerve injury has occurred
2. The bladder demonstrates Cannon's Law of Denervation Supersensitivity - a denervated organ becomes hypersensitive to its natural neurotransmitter because it upregulates receptors in the absence of nerve-mediated stimulation

Core Conceptual Difference

In simple terms: All denervated bladders are atonic, but not all atonic bladders are denervated.

Causes Compared

Causes of Atonic Bladder (All Types)

Causes of Denervated Bladder (Specific to Nerve Damage)

Pathophysiology Compared

Atonic Bladder (General)

• Detrusor smooth muscle fails to generate adequate contraction
• Bladder fills passively until overflow incontinence occurs
• Mechanism may be neurogenic (no nerve signal) OR myogenic (muscle itself is damaged/fibrosed)
• Post-void residual (PVR) is high
• On urodynamics: acontractile or underactive detrusor pattern

Denervated Bladder (Specific)

• Nerve supply is structurally disrupted
• The detrusor muscle itself may be structurally intact initially, but cannot contract without neural input
• Over time, Cannon's Law of Denervation Supersensitivity develops:
  • Denervated detrusor upregulates muscarinic (cholinergic) receptors
  • The muscle becomes hypersensitive to bethanechol and acetylcholine
  • Adrenergic nerve terminals in denervated human detrusors become thicker and denser (PMC underactive bladder review)
• This is exploited in the Bethanechol Supersensitivity Test: subcutaneous bethanechol causes a rise of ≥15 cmH2O above baseline in a truly denervated bladder (positive test), whereas a myogenically impaired bladder shows < 15 cmH2O rise
  • Note: test has only ~76% sensitivity and 50% specificity, so it is not definitive (Campbell Walsh)
• Parasympathetic denervation (pelvic splanchnic nerve injury) → acontractile detrusor
• Sympathetic denervation (hypogastric nerve injury) → loss of bladder compliance + open bladder neck
• Mixed injury to pelvic plexus → combined patterns

Clinical Features Compared

Urodynamic Differences

Treatment - Where They Differ

Summary in One Paragraph

• Campbell Walsh Wein Urology - Normal Voiding and Emptying; Pathogenesis
• Comprehensive Clinical Nephrology, 7th Ed. - Neurologic Diseases of the Lower Urinary Tract
• Pfenninger & Fowler's Procedures for Primary Care - Bethanechol Testing
• Neuroanatomy through Clinical Cases, 3rd Ed. - Bladder Function
• Bradley & Daroff's Neurology in Clinical Practice - Spinal Cord Injury and Bladder Function